Statins fail to reduce cardiovascular mortality or events in primary prevention (treating high LDL in people without prior heart disease), and when they do show benefit in secondary prevention, the mean increase in lifespan is only four days, with a number needed to treat of 754 (meaning you must treat 754 people for one to benefit), far exceeding the threshold of cost-effectiveness